Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07539454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nirogacestat in Patients With Kaposi Sarcoma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.
Trial Details
NCT Number NCT07539454
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 AIDS-Related Kaposi Sarcoma, Skin Kaposi Sarcoma
Related terms AIDS-related Kaposi sarcoma
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov